More than 10 million people present to emergency departments and doctors' offices with chest pain symptoms each year. Coronary computed tomographic angiography offers clinicians the ability to visualize the coronary arteries of their patients without the risks of invasive angiography. The Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial compared clinical outcomes from the initial use of coronary computed tomographic angiography versus functional (stress) testing in 10 003 patients with chest pain and low to intermediate coronary artery disease risk and found no difference in clinical outcomes between the testing strategies. Patient-reported outcomes related to quality of life were also assessed as part of the trial. We found no significant differences in quality-of-life outcomes between groups through 2 years of follow-up. Both diagnostic testing strategies resulted in similar improvements in quality of life, and there were few differences in patient care seen after a positive test result. Both groups reported decreased quality of life at baseline, and both groups showed high levels of chest pain resolution by 6 months. This quality-of-life substudy demonstrates for the first time that the selection of diagnostic tests for patients with stable chest pain may be made based on availability and clinician and patient preference without significantly impacting patient-reported outcomes. See p 1995.
Obstructive Sleep Apnea and Cardiovascular Events After Percutaneous Coronary Intervention
The Sleep and Stent Study studied 1311 patients in 5 countries who completed a sleep study within 7 days of percutaneous coronary intervention. Drug-eluting stents were implanted in 80.1% of these patients. Obstructive sleep apnea (OSA), defined as an apnea-hypopnea index of ≥15 events per hour, was found in 45.3%. Patients' mean body mass index was 25.7±3.7 kg/m2. Their rates of overweight (body mass index, 25-30 kg/m2) and obesity (>30 kg/m2) were 42% and 13%, respectively. During a median follow-up of 1.9 years (interquartile range, 0.8 years), 141 patients experienced major adverse cardiac and cerebrovascular events (3-year cumulative incidence estimate, 16.4%). The crude incidence of a major adverse cardiac and cerebrovascular event was higher in the OSA group than in the non-OSA group (3-year estimate, 18.9% versus 14.0%; p=0.001). Likewise, the crude incidence of cardiovascular mortality (3-year estimate, 4.2% versus 1.7%; p=0.035) and all-cause mortality (3-year estimate, 6.5% versus 4.6%; p=0.047) was also higher in the OSA group. OSA was found to be an independent predictor of a major adverse cardiac and cerebrovascular events after adjustment for age, sex, ethnicity, body mass index, hypertension, and diabetes mellitus (adjusted hazard ratio, 1.57; 95% confidence interval, 1.10-2.24; p=0.013). In summary, OSA is independently associated with a future major adverse cardiac and cerebrovascular event in patients undergoing percutaneous coronary intervention. Future studies to evaluate therapeutic approaches to mitigate OSA-associated risk are warranted. See p 2008.
Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism: A Population-Based Study
This observational study analyzed outcomes associated with inferior vena cava filter (VCF) use in 85 159 patients who were hospitalized for acute venous thromboembolism. There was a statistically significant 30% reduction in the 30-and 90-day risk of death in the patient treated with a VCF versus no VCF, but this was observed only in the small subgroup of patients (3.5%) who had active bleeding. Among patients who underwent major surgery immediately before or during the acute venous thromboembolism hospitalization (1.8%), use of a VCF was not beneficial. In the remaining 80 697 patients who had no contraindication to anticoagulation therapy (95%), use of a VCF (n=7762) had no effect on survival or the risk of developing a pulmonary embolism within 1 year, but VCF use increased the risk of recurrent deep vein thrombosis by 50%. These findings were similar to the results of 2 small, randomized studies that reported that use of a VCF did not reduce the risk of subsequent pulmonary embolism but led to an increase in the risk of developing a new deep vein thrombosis. The findings of this study are in alignment with the recent 2016 American College of Chest Physicians antithrombotic therapy for venous thromboembolism disease guidelines, which recommend that a VCF not be inserted in patients with acute venous thromboembolism who can be treated with standard anticoagulation therapy. In light of the American Board of Internal Medicine's Choosing Wisely initiative, the implications are straightforward: A VCF should not be used if the patient can receive standard anticoagulation therapy. See p 2018.
Hospice Use Following Implantable Cardioverter-Defibrillator Implantation in Older Patients: Results From the National Cardiovascular Data Registry
Although hospice is the main provider of end-of-life care in the United States, its use among patients with implantable cardioverter-defibrillators (ICDs) is unknown. This report leveraged data from National Cardiovascular Data Registry-ICD Registry linked to Medicare claims to describe the incidence and features of hospice use in a large, nationally representative sample of older patients following ICD implantation. Among 194 969 ICD recipients, after accounting for the competing risk of death, the cumulative incidence rate of hospice admission in the 5 years following ICD placement was 21%, with factors including cancer, dementia, older age, heart failure severity, and regional penetration of hospice care most strongly associated with a shorter time to hospice enrollment. Volume 133 ◼ Number 21 ◼ May 24, 2016
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Overall, our finding that substantial numbers of ICD recipients use hospice services underscores the need for hospice providers to prepare to care for dying ICD patients, including establishing protocols for identifying and turning off such devices and avoiding shocks at the end of life. At the same time, 63% of decedents did not receive hospice care, and lengths of stay for hospice enrollment were relatively short. These findings, coupled with the fact that, at 5 years postimplantation, 51% of older ICD patients were either dead or in hospice, calls for a much greater understanding of the broader palliative care needs of older ICD patients and improved strategies to deliver that care. See p 2030.
Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure
Heart failure is a leading cause of mortality and hospitalization, and effective therapies remain elusive. The present study uncovers that branched-chain amino acid (BCAA; including leucine, isoleucine, and valine) catabolic defect is a hallmark of metabolic changes in murine failing heart and human dilated cardiomyopathy hearts. Accumulation of branchedchain α-keto acids resulting from BCAA catabolic defect directly impairs mitochondrial activity, induces oxidative stress, and promotes cardiac dysfunction. More importantly, restoration of BCAA catabolism by pharmacological agents blunt disease progression in pressure overload-induced heart failure. Therefore, defects in BCAA/branched-chain α-keto acids catabolism are not only a new metabolic biomarker for heart failure, but also a significant contributor to heart failure. Promoting BCAA catabolic activity with a pharmacological agent can be a potentially effective therapeutic strategy to ameliorate the pathogenic progression of heart failure. Finally, considering the dietary source of BCAA, the present study indicates a role of protein intake in the disease progression of heart failure and thus serves as a preclinical basis to develop a more appropriate nutritional intervention approach for this disease. See p 2038.
Smooth Muscle Enriched Long Noncoding RNA (SMILR) Regulates Cell Proliferation
Long noncoding RNAs (lncRNAs) are a relatively new class of discovered RNA molecules that possess important regulatory functions. The rapidly expanding catalogue of lncRNAs holds promise that, in the near future, lncRNAs might become relevant to vascular disease clinically as possible biomarkers of cardiovascular events and for targeted treatment of disease. Our work indicates that dysregulation of key lncRNAs may have profound implications in regulating vascular smooth muscle cell function. In addition, we detected the release of this lncRNA in plasma samples and correlated with inflammatory C-reactive protein levels, highlighting new methods and possibilities for improved detection. The emergence of lncRNAs as regulators of gene expression and vascular function will undoubtedly alter our understanding of the complex regulation network of cell function underpinning clinical vascular disease. See p 2050.
